anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Day surgery is developing and its popularity is increasing for a variety of reasons: economic constraints, changes in professional practices, a greater adhesion of the patient. In an era of progress in surgical procedures, pedicled-perforator flaps reducing donor site morbidity and avoiding micro-anastomosis could take their place in Day surgery if planned and managed by an experienced team.
METHODS: In the period January 2019 to January 2021, we performed perforator flaps for soft tissue coverage in ambulatory setting. The patients were included retrospectively and data were collected by reviewing the medical records. Major and minor complications were recorded.
RESULTS: The retrospective cohort included 32 surgical procedures in 32 patients. In all cases, perforator flaps were realized for resurfacing soft tissue defects consequent to oncodermatology surgery (84.3%), soft tissue sarcoma surgery (12.5%), invasive ductal breast carcinoma (3.1%). Major complications needing a surgical revision overcame 3/32 times (9.4%). In these cases, a failure requiring the drop off the flap overcame once. The average wound healing time was of 33 days (15-90) and the mean duration of follow-up was 9.6 months (1-22).
CONCLUSION: The low complication rate in our series suggests that this first experience on perforator flaps in outpatient surgery is promising in terms of safety and feasibility. Day surgery could be a practical option for this type of surgical procedures avoiding the conventional department's saturation and allowing the delivery of proper surgical cares.
This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
Tablets of stable colour comprise acetyl salicylic acid, codeine or a salt thereof, for example, the phosphate, maize starch, talc, and a silicone fluid, for example, a polydimethylsiloxane, having a viscosity of from 1000 to 1,000,000 (preferably 50,000 to 200,000) centistokes, the proportion of silicone fluid to talc being from 4 to 20 per cent by weight, conveniently 8 to 12 per cent.  Phenacitin or other oral medicaments may also be included.  The silicone and talc is first mixed, for example, by adding a 25 per cent w./w. solution of the silicone in a volatile organic solvent, e.g. chloroform or carbon tetrachloride, to the talc and removing the solvent.  This mixture is then mixed with the remaining ingredients and tableted. The silicone may also be mixed with the talc in the form of an aqueous emulsion, e.g. diluted "Releasil (Registered Trade Mark) No. 8."
Methods and systems are provided for detecting a mental health condition. Structured and unstructured information is analyzed using natural language processing to extract information including clinical data values and medical concepts pertaining to a user. Reference medical information is evaluated using natural language processing to correlate medical data with mental health conditions. A classification for a mental health condition of the user is determined using a machine learning model and based on the extracted information and correlations, wherein the extracted information includes blood analysis for the user. The user is assigned to a segment of users based on the extracted information. A treatment for the mental health condition of the user is indicated based on the classification and the assigned segment of users.
PURPOSE: The exact etiology of Bell's palsy (BP) remains unknown, while its potential etiopathology includes neuritis and inflammation-related demyelination as in optic neuritis. It has been reported that disruption of heavy metal homeostasis may be associated with the inflammatory process of optic neuritis; therefore, heavy metals may be involved in the pathogenesis of facial nerve neuritis. In this study, we aimed to investigate serum levels of heavy metals including essential elements [iron (Fe), zinc (Zn), copper (Cu), cobalt (Co), and manganese (Mn)], and nonessential elements [lead (Pb) and cadmium (Cd)] in patients with BP.
METHODS: The study included 25 patients with BP and 31 healthy volunteers. For each participant, serum levels of essential and nonessential elements were measured using the atomic absorption spectrophotometer method.
RESULTS: Serum levels of essential elements were significantly lower in the patient group compared to the control group (p < 0.001, for each). Serum levels of Pb increased in the patient group compared to the control group although no significant difference was achieved (p = 0.105). In contrast, serum Cd levels increased significantly in the patient group compared to the control group (p < 0.001).
CONCLUSION: Our findings suggest that decreased essential and increased nonessential elements may be associated with BP and thus, serum concentrations of these elements should be taken into account in BP. Studies are warranted to determine the role of these elements in treatment of BP.
BACKGROUND: Cellulite represents a common multi-factorial condition that affects nearly all women and is now recognized as a clinical condition associated with systemic factors and negative psychological effects. Several noninvasive and minimally invasive treatments were developed during the last few years, but limited evidence supports many of them due to lack of evidence, insufficient participants, and potential adverse effects.
METHODS: This study aimed to evaluate the efficacy of a seaweed mud application in improving both the structure and function of tissues affected by cellulite. Sixty women with cellulite underwent 4-week applications of seaweed mud on the buttocks and thighs. The following assessments were performed at baseline and after the last treatment: photographic, clinical, and anthropometric evaluation; tests for elasticity and hydration; ultrasonography of cellulite nodules; and cellulite biopsies in the trochanteric region. Patient satisfaction was assessed using a 5-point Likert-scale questionnaire.
RESULTS: The treatment resulted in a significant improvement in the severity of cellulite severity between the initial assessment and the 4-week follow-up, with enhanced structure, elasticity, and hydration of the affected tissues. Microscopic analysis of the cellulite biopsies revealed a significant restoration of dermal organization with induced collagen synthesis and reduced inflammation, edema, and lipid deposition following the 4-week seaweed mud applications. Additionally, the treatment led to a remarkable improvement in comfort and satisfaction as well as a reduction in body circumferences.
CONCLUSIONS: The cosmetic application of seaweed mud has proven to be a safe, non-invasive treatment for improving the tissue alterations characteristic of cellulite.
All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Thereafter, participants in the Difficult group will undergo training involving discriminations between highly similar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
The following adverse events have been identified during postapproval use of levetiracetam. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.

In addition to the adverse experiences listed above, the following have been reported in patients receiving marketed levetiracetam worldwide. The listing is alphabetized: abnormal liver function test, hepatic failure, hepatitis, leukopenia, neutropenia, pancreatitis, pancytopenia (with bone marrow suppression identified in some of these cases), thrombocytopenia, and weight loss. Alopecia has been reported with levetiracetam use; recovery was observed in majority of cases where levetiracetam was discontinued. These adverse experiences have not been listed above, and data are insufficient to support an estimate of their incidence or to establish causation.
The invention provides a celecoxib chewable tablet and a preparation method thereof. The celecoxib chewable tablet consists of the following raw materials in percentage by weight: 5-30% of celecoxib, 5-20% of disintegrating agent, 20-80% of filler, 5-30% of adhesive, 0.5-5% of flow aid and 0.5-3% of surfactant. The celecoxib chewable tablet has the advantages of both tablets and fluid preparations and has the characteristics of even dispersion, very short disintegrating time limit, fast medicament dissolution and high bioavailability, and is better convenience to take. The celecoxib chewable tablet is especially suitable for the aged and the patients who have swallowing difficulties. Upon inspection, the celecoxib chewable tablet shows that the quality indexes such as content, characteristics, identification, disintegrating time limit and dissolution accord with the 2010 edition of China Pharmacopoeia and relevant regulations. The bioavailability of the celecoxib chewable tablet is higher than the tablets on sale.
Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the PH FDC SC for a total of 18 cycles.
Participants included in this group should have normal ovarian reserve: number of antral follicle count ≥5, level of anti-Mullerian hormone ≥1.2 ng/ml, and number of oocytes retrieved in the present IVF-ET cycles\>9. All participants in this group receive the standard operation protocol for In vitro fertilization and embryo transfer.
The present invention relates to a novel class of Silicon derivatives. The Silicon compounds can be used to treat cancer. The Silicon compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the Silicon derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the Silicon derivatives in vivo.
BACKGROUND: Sepsis is a life-threatening syndrome characterized by acute loss of organ function due to infection. Sepsis survivors are at risk for long-term comorbidities, have a reduced Quality of Life (QoL), and are prone to increased long-term mortality. The societal impact of sepsis includes its disease burden and indirect economic costs. However, these societal costs of sepsis are not fully understood. This study assessed sepsis's disease-related and indirect economic costs in the Netherlands.
METHODS: Sepsis prevalence, incidence, sepsis-related mortality, hospitalizations, life expectancy, QoL population norms, QoL reduction after sepsis, and healthcare use post-sepsis were obtained from previous literature and Statistics Netherlands. We used these data to estimate annual Quality-adjusted Life Years (QALYs), productivity loss, and increase in healthcare use post-sepsis. A sensitivity analysis was performed to analyze the burden and indirect economic costs of sepsis under alternative assumptions, resulting in a baseline, low, and high estimated burden. The results are presented as a baseline (low-high burden) estimate.
RESULTS: The annual disease burden of sepsis is approximately 57,304 (24,398-96,244; low-high burden) QALYs. Of this, mortality accounts for 26,898 (23,166-31,577) QALYs, QoL decrease post-sepsis accounts for 30,406 (1232-64,667) QALYs. The indirect economic burden, attributed to lost productivity and increased healthcare expenditure, is estimated at €416.1 (147.1-610.7) million utilizing the friction cost approach and €3.1 (0.4-5.7) billion using the human capital method. Cumulatively, the combined disease and indirect economic burdens range from €3.8 billion (friction method) to €6.5 billion (human capital method) annually within the Netherlands.
CONCLUSIONS: Sepsis and its complications pose a substantial disease and indirect economic burden to the Netherlands, with an indirect economic burden due to production loss that is potentially larger than the burden due to coronary heart disease or stroke. Our results emphasize the need for future studies to prevent sepsis, saving downstream costs and decreasing the economic burden.
The exercises were conducted at a heart rate of 50-70% of maximum heart rate for 30 minutes. Exercises were included strengthening muscles groups (shoulder flexors, extensors, abductor's muscles, hip flexors, extensor muscles, knee flexors, extensor muscles, abdominal muscles, and back muscles).
The technology disclosed relates to a system and method for assigning participants to groups in a clinical trial. The system includes a federated server configured with group assignability data specifying a plurality of groups assignable to participants in a clinical trial and group distribution data specifying distribution of the participants into groups. The groups include at least one placebo group and one or more treatment groups. The system includes an intervention server configured to generate group encryption keys for encrypting the group assignability data. The system includes edge devices of each of the participants. The edge devices are in communication with the federated server.
BACKGROUND: In the early postoperative stage after heart transplantation, there is a lack of predictive tools to guide postoperative management. Whether the vasoactive-inotropic score (VIS) can aid this prediction is not well illustrated.
METHODS: In total, 325 adult patients who underwent heart transplantation at our center between January 2015 and December 2018 were included. The maximum VIS (VISmax) within 24 h postoperatively was calculated. The Kaplan-Meier method was used for survival analysis. A logistic regression model was established to determine independent risk factors and to develop a nomogram for a composite severe adverse outcome combining early mortality and morbidity.
RESULTS: VISmax was significantly associated with extensive early outcomes such as early death, renal injury, cardiac reoperation and mechanical circulatory support in a grade-dependent manner, and also predicted 90-day and 1-year survival (p < 0.05). A VIS-based nomogram for the severe adverse outcome was developed that included VISmax, preoperative advanced heart failure treatment, hemoglobin and serum creatinine. The nomogram was well calibrated (Hosmer-Lemeshow p = 0.424) with moderate to strong discrimination (C-index = 0.745) and good clinical utility.
CONCLUSION: VISmax is a valuable prognostic index in heart transplantation. In the early post-transplant stage, this VIS-based nomogram can easily aid intensive care clinicians in inferring recipient status and guiding postoperative management.
Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
Participants who received study drug in the order: Potassium Magnesium Citrate (KMgCit) powder, Potassium Citrate (KCit) powder, Potassium Chloride (KCl) powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
Clinical trials have, in general, formally demonstrated the effectiveness and safety of various autologous therapies for the treatment of knee OA. Differences in the processing of autologous therapies can yield substantial differences in the resulting output. It appears that the safety of autologous therapies is roughly equivalent across different processing methods. However, making generalizations regarding the effectiveness across these autologous therapies is more complicated. Thus, each autologous therapy requires independent efficacy evaluation. nSTRIDE APS has been shown to decrease pain, increase function and have a favorable safety profile in a small pilot trial. However, demonstration of the treatment effects in a more heterogeneous population is lacking. Further, neither the effect time course nor the utility of multiple injections has been documented. This study will allow for low burden, efficient data collection in a larger heterogeneous population of persons suffering from knee OA. The study will document the treatment effects and timeline of treatment effects for nSTRIDE APS following single or repeated injections.
This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
PURPOSE:To obtain the titled ulcer having high safety containing an active ingredient extracted from a plant of the family Iridaceae. CONSTITUTION:Rhizome of plant of the genus Iris of the family Iridaceae is thinly cut, dried and extracted with an alcohol such as methanol while stirring at 10-80 deg.C give essence. The essence is suspended in water, mixed with an ether (e.g. ethyl ether) and then ether layer is removed to give an ether-insoluble fraction. The water layer is mixed with a slightly soluble alcohol (e.g. n-butanol) and the alcohol layer is partitioned and extracted to give the active ingredient of anti-peptic ulcer agent (solubility: readily soluble in methanol and slightly soluble in ethyl ether; total nitrogen amount: <=5.0wt.% color reaction: positive in anthrone sulfuric acid reaction, Liebermann reaction and diazo reaction). Powder, tablet, capsule and solution are preferably as the dosage form. A dose is preferably 1,000mg/kg/day and administered dividedly about three times daily.
Congenital myotonic dystrophy type 1 (CDM1) is a rare neuromuscular disease. The aim of our study was to evaluate clinical variability of CDM1 and factors that may influence survival in CDM1. Research included 24 pediatric patients with CDM1. Most of our patients had some form of hypoxic ischemic encephalopathy (HIE) (74 %), from mild to severe. Prolonged and complicated deliveries (75 %), high percentage of children resuscitated at birth (57 %) and respiratory insufficiency (46 %) with consequent hypoxia were the main reasons that could explain high percentage of HIE. Therapeutic hypothermia was applied in three children with poor outcome. Median survival of all CDM1 was 14.2 ± 1.5 years. Six patients had a fatal outcome (25 %). Their mean age of death was 3.0 ± 2.8 years. Poor prognostic factors for the survival of our CDM1 patients were: preterm delivery, resuscitation at birth, severe HIE, hypothermia treatment and permanent mechanical ventilation. Respiratory insufficiency was the main life-threatening factor. Our data clearly indicates the need to develop natural history studies in CDM1 in order to enhance the standards of care and to develop clinical trials investigating causative therapies in pediatric patients with CDM1.
A suppository containing at least two therapeutically active ingredients is divided transversely into two portions abutting end to end one or more active ingredients being confined to one portion, and one or more other ingredients being confined to the other.  The intended leading end of the suppository contains an anti-inflammatory or decongestant agent e.g. aminophyllin, adrenaline or phenylephrine and the other portion contains an analgesic or local anaesthetic e.g. cocaine, codeine, morphine, barbiturates, procaine and amethocaine. The two portions may be cast separately, the ends melted and touched together or they may be cast successively in the same mould. Anti-septics and astringents may be included together with conventional suppository bases.
PURPOSE: A composition and a cosmetic composition containing Ulmi Pasta Semen extract is provided to effectively prevent and treat brain cancer. CONSTITUTION: A composition for preventing and treating brain cancer contains ethanol extract of Ulmi Pasta Semen as an active ingredient. The ethanol extract is prepared by extracting Ulmi Pasta Semen at 50 Deg. C for 24 hours. The composition also contains pharmaceutically acceptable carrier or diluents. A cosmetic composition for preventing brain cancer contains the ethanol extract and cosmetically acceptable additive as an active ingredient.
Paroxetine tablets should be administered as a single daily dose with or without food, usually in the morning. The recommended dose of paroxetine tablets in the treatment of OCD is 40 mg daily. Patients should be started on 20 mg/day and the dose can be increased in 10 mg/day increments. Dose changes should occur at intervals of at least one week. Patients were dosed in a range of 20 to 60 mg/day in the clinical trials demonstrating the effectiveness of paroxetine tablets in the treatment of OCD. The maximum dosage should not exceed 60 mg/day.
The invention discloses a bispecific antibody targeting HER2 and PD-L1, and a preparation method and application thereof. The bispecific antibody comprises a first protein functional region that targets HER2 and a second protein functional region that targets PD-L1; the first protein functional region comprises a VL comprising three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the sequence shown as SEQ ID NO. 3 and a VH comprising three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the sequence shown as SEQ ID NO. 4; the second protein functional region comprises a VHH comprising three complementarity determining regions CDR1, CDR2 and CDR3 comprised in the sequence as shown in SEQ ID No. 2. The bispecific antibody has better purity and thermal stability; binding activities to both targets are close to corresponding monoclonal antibodies, the activity of blocking PD-1/PD-L1 is equivalent to that of the corresponding monoclonal antibodies, and the activity of inhibiting SK-BR-3 cell proliferation is equivalent to that of the corresponding monoclonal antibodies; and simultaneously, the compound has good ADCC activity and in-vivo tumor inhibition activity.
Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.